Vanda Pharmaceuticals Ltd withdraws its marketing authorisation application for Fanaptum (iloperidone)

Source: No information given Area: News The European Medicines Agency has been formally notified by Vanda Pharmaceuticals Ltd of its decision to withdraw its application for a centralised marketing authorisation for the medicine Fanaptum® (iloperidone) intended to be used for the treatment of schizophrenia.   In its official letter, the company stated that it is withdrawing the application because the CHMP identified missing data which will not be available in a timeframe acceptable in the centralised procedure.
Source: NeLM - Mental Health - Category: Psychiatry Source Type: news